1 Introduction Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells and regulates blood sugar by increasing insulin while reducing glucagon secretion and inhibiting stomach emptying and food intake ( Ocular diseases, including glaucoma, diabetic retinopathy (DR), and age-related macular degeneration (AMD), impose a staggering global burden, with glaucoma alone affecting 95 million individuals and causing irreversible vision loss in over 10 million ( Emerging evidence positions GLP-1RAs as a transformative candidate for ocular therapeutics
Beyond glucose control, Tirzepatide also slows gastric emptying, meaning food takes longer to move from the stomach to the small intestine
They also provide women and men health services, including hormone therapy options
Sermorelin mimics natural growth hormone-releasing hormone, stimulating the pituitary through the GHRH receptor pathway to support pulsatile GH release
C-terminal amidation supports conformational stability and consistent receptor interaction during in vitro analysis
This medication is also not intended for treating type 1 diabetes or a related complication known as diabetic ketoacidosis